All peptides
Setmelanotide
Also known as: Imcivree
FDA-Approved
Setmelanotide is a melanocortin-4 receptor agonist approved for chronic weight management in patients with certain rare genetic obesities (POMC, PCSK1, LEPR deficiency, and Bardet-Biedl syndrome).
Buy Setmelanotide on American Peptides
Affiliate link — we may earn a commission at no extra cost to you.
Overview
Setmelanotide is a melanocortin-4 receptor agonist approved for chronic weight management in patients with certain rare genetic obesities (POMC, PCSK1, LEPR deficiency, and Bardet-Biedl syndrome).
FDA Approval Status
Approved by the FDA for at least one medical indication (see approved uses below).
Mechanism of Action
Selective MC4R agonism restores signaling in the leptin-melanocortin pathway.
Current Research
Pivotal Phase III trials demonstrated meaningful weight loss in eligible genotypes.
Research strength: Strong
Potential Medical Uses
- POMC/PCSK1/LEPR deficiency obesity
- Bardet-Biedl syndrome
Potential Benefits
- Weight loss in genetically defined obesity
- Reduced hyperphagia
Known Side Effects
- Skin hyperpigmentation
- Nausea
- Injection-site reactions
- Depression (monitor)
Contraindications
- Hypersensitivity
Drug Interactions
- No major documented
Administration Methods
- Subcutaneous injection daily
Half-life
~11 hours
Reconstitution
Prefilled vial.
Storage & Handling
Refrigerate.
References & Sources
Frequently Asked Questions
Information on this page is educational and general in nature. It is not medical advice. Consult a qualified healthcare professional before making any medical decisions.